The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab (pembro) versus investigator’s choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC): 5-year follow-up from the phase 3 KEYNOTE-045 trial.
 
Joaquim Bellmunt
No Relationships to Disclose
 
Andrea Necchi
No Relationships to Disclose
 
Ronald De Wit
No Relationships to Disclose
 
Jae-Lyun Lee
No Relationships to Disclose
 
Lawrence Fong
No Relationships to Disclose
 
Nicholas J. Vogelzang
No Relationships to Disclose
 
Miguel A. Climent Durán
No Relationships to Disclose
 
Daniel P. Petrylak
No Relationships to Disclose
 
Toni K. Choueiri
No Relationships to Disclose
 
Winald R. Gerritsen
No Relationships to Disclose
 
Howard Gurney
No Relationships to Disclose
 
David I. Quinn
No Relationships to Disclose
 
Stephane Culine
No Relationships to Disclose
 
Cora N. Sternberg
No Relationships to Disclose
 
Jin Zhi Xu
No Relationships to Disclose
 
Blanca Homet Moreno
No Relationships to Disclose
 
James Luke Godwin
No Relationships to Disclose
 
Dean F. Bajorin
No Relationships to Disclose
 
David J. Vaughn
No Relationships to Disclose
 
Yves Fradet
No Relationships to Disclose